Forward Pharma A/S is a biopharmaceutical company. The Company is focusing to initiate a Phase III clinical trial using FP187, a formulation of dimethyl fumarate (DMF), for the treatment of multiple sclerosis (MS), patients. FP187, the Company�s clinical candidate, is a DMF formulation in a delayed and slow release oral dose, which it plans to advance for the treatment of relapsing remitting MS, or RRMS, and other immune disorders, such as psoriasis.